Serotonin uptake inhibition by the monoamine oxidase inhibitor brofaromine

Waldmeier, P. C.; T, Graf; Germer, M.; Feldtrauer, Jean-Jacques; Howald, H.

doi:10.1016/0006-3223(93)90327-a

Cited by 7 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparison of clinical dosages of these compounds suggests that 5-HT uptake inhibition might synergize with brofaromine's MAO inhibitory effect in its therapeutic action (Waldmeier, 1993). Evidence that 5-HT uptake inhibition does occur at clinical doses of brofaromine was obtained in platelet studies in volunteers (Waldmeier et al, 1993b) and patients (Celada et al, 1992).…”

Section: Neurobiochemandtrymentioning

confidence: 97%

Brofaromine ? a review of its pharmacological properties and therapeutic use

Volz

Gleiter

Waldmeier³

et al. 1996

J. Neural Transmission

View full text Add to dashboard Cite

The antidepressant activity of monoamine oxidase inhibitors has been well established for 30 years. Nevertheless, this group of compounds was handled with great care, mainly because of the interaction potential with tyramine-containing foodstuff. With the discovery of reversible and selective inhibitors of monoamine oxidase type A a renaissance of these compounds has begun. In this paper one of these new substances--brofaromine--will be described in detail. Biochemical and pharmacological aspects will be reviewed, showing that brofaromine is a selective and reversible inhibitor of monoamine oxidase type A with additional serotonin reuptake inhibiting properties. Both mechanisms of action may synergize in the antidepressant effect of the compound. The main results of clinical trials in depression and other indication areas will also be covered. Special attention will be put on the side effect profile.

show abstract

Section: Neurobiochemandtrymentioning

confidence: 97%

Brofaromine ? a review of its pharmacological properties and therapeutic use

Volz

Gleiter

Waldmeier³

et al. 1996

J. Neural Transmission

View full text Add to dashboard Cite

show abstract

“…One of the authors (D.B.) of the present paper conducted a number of clinical trials with the experimental drug, brofaromine, a RIMA with SSRI properties (Waldmeier et al, 1993). It exhibited good efficacy in the treatment of major depression (Chouinard et al, 1993) and panic disorder (Bakish et a [., 1993;Bakish, 1994).…”

Section: Introductionmentioning

confidence: 99%

Moclobemide and specific serotonin re‐uptake inhibitor combination treatment of resistant anxiety and depressive disorders

Bakish

Hooper

West

et al. 1995

Human Psychopharmacology

View full text Add to dashboard Cite

This retrospective study was undertaken with the objective of determining how effective and safe moclobemide, a specific and reversible inhibitor of monoamine oxidase-A (RIMA), is when used in combination with specific serotonin re-uptake inhibitors (SSRIs), in a clinical setting. A thorough chart review was done of all patients with affective and anxiety disorders seen at our centre who received combination treatment with moclobemide and an SSRI. Combination moclobemide-SSRI treatment demonstrated good efficacy in treating treatment-resistant patients. The combination treatment was well tolerated with very few drug interactions. Dosages should be started low, titrated slowly and carefully, and patients should be monitored closely.

show abstract

Monoamine oxidase inhibitors (including the newer reversible compounds)

Buller

Karin

2000

Anxiolytics

View full text Add to dashboard Cite

Serotonin uptake inhibition by the monoamine oxidase inhibitor brofaromine

Cited by 7 publications

References 17 publications

Brofaromine ? a review of its pharmacological properties and therapeutic use

Brofaromine ? a review of its pharmacological properties and therapeutic use

Moclobemide and specific serotonin re‐uptake inhibitor combination treatment of resistant anxiety and depressive disorders

Monoamine oxidase inhibitors (including the newer reversible compounds)

Contact Info

Product

Resources

About